Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Motus GI Holdings, Inc. (MOTS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.4294-0.0258 (-5.67%)
At close: 04:00PM EST
0.4392 +0.01 (+2.28%)
After hours: 07:22PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4552
Open0.4500
Bid0.4270 x 800
Ask0.4293 x 1800
Day's Range0.4207 - 0.4535
52 Week Range0.4207 - 2.7400
Volume669,941
Avg. Volume843,538
Market Cap20.087M
Beta (5Y Monthly)2.54
PE Ratio (TTM)N/A
EPS (TTM)-0.6640
Earnings DateNov 10, 2021 - Nov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.03
  • GlobeNewswire

    Motus GI to Present at Two Upcoming Investor Conferences in December 2021

    FORT LAUDERDALE, Fla., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to present at two upcoming investor conferences in December 2021. 33rd Annual Piper Sandler Healthcare ConferenceMeetin

  • Simply Wall St.

    Is Motus GI Holdings (NASDAQ:MOTS) A Risky Investment?

    Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

  • GlobeNewswire

    Motus GI Reports Third Quarter 2021 Financial Results and Provides Corporate Update

    Reported approximately 40% increase in revenue compared to Q2 2021On track to file a 510(k) submission to FDA by end of 2021 for Pure-Vu EVS, an advanced, next-generation system that will enhance procedural ease of use and speed of deploymentDesigning a multi-center, randomized controlled trial to support reimbursement of Pure-Vu for high need outpatients, a subset of the US market of more than 20 million total annual colonoscopies FORT LAUDERDALE, Fla., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Motus G

Advertisement
Advertisement